MainStreet Investment Advisors LLC acquired new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) in the fourth quarter, according to the company’s latest 13F file filed with the U.S. Securities and Exchange Commission (SEC). The fund acquired 5,199 shares of the medical device provider’s stock, according to the company. Its value is approximately $663,000.
Other big investors have also changed positions in the company. Crossmark Global Holdings Inc. increased his stake in Zimmer Biomet by 0.7% in the third quarter. Crossmark Global Holdings Inc. now owns 14,006 shares of the medical device provider worth $1,464,000 after acquiring an additional 91 shares during the previous quarter. HB Wealth Management LLC increased its stake in Zimmer Biomet by 4.0% in the fourth quarter. HB Wealth Management LLC now owns 2,371 shares of the medical device provider, valued at $302,000, after acquiring an additional 92 shares during the previous quarter. Creative Financial Designs Inc. ADV increased its stake in Zimmer Biomet by 21.3% in the third quarter. Creative Financial Designs Inc. ADV owns 563 shares of the medical device provider worth $59,000 after acquiring an additional 99 shares during the previous quarter. Farmers & Merchants Investments Inc. increased its stake in Zimmer Biomet by 5.8% in the third quarter. Farmers & Merchants Investments Inc. now owns 1,860 shares of the medical device provider worth $194,000 after acquiring an additional 102 shares during the previous quarter. Finally, DAVENPORT & Co LLC increased its stake in Zimmer Biomet by 2.9% in the third quarter. DAVENPORT & Co LLC now owns 3,795 shares worth $397,000 in the medical device provider after acquiring an additional 106 shares during the previous quarter. 87.21% of the shares are currently owned by hedge funds and other institutional investors.
Analyst sets new price target
ZBH has been the topic of several analyst reports. StockNews.com began covering Zimmer Biomet in a research note on Thursday, March 16th. They have set a “buy” rating on the stock. UBS Group undertook coverage for Zimmer Biomet in an investigative report on Tuesday, March 28. They set a “sell” rating for the company and a target price of $112.00. Jefferies Financial Group upgraded Zimmer Biomet’s rating from ‘underperform’ to ‘hold’ and raised the company’s price target from $115.00 to $130.00 in a research report on Friday, March 31. Raymond James raised Zimmer Biomet from a “market execution” rating to an “outperform” rating in a research report on Thursday, January 5, and he set a price target for the company at $144.00. Finally, Morgan Stanley raised Zimmer Biomet’s target price from $135.00 to $140.00, giving the company an “equal-weighted” rating in its research report on Monday, February 6. Two analysts gave a sell rating, six gave a hold rating, and seven analysts gave the company a buy rating. According to MarketBeat.com data, Zimmer Biomet currently has an average rating of “hold” and a consensus target price of $134.19.
Zimmer Biomet stock up 0.2%
Zimmer Biomet shares opened Friday at $138.35. His 50-day moving average for this business is $126.96 and his 200-day moving average is $121.94. The company has a quick ratio of 0.97, a current ratio of 1.88 and a debt to equity ratio of 0.43. The company has a market capitalization of $28.91 billion, a P/E ratio of 125.77, a P/E/G ratio of 3.08 and a beta of 1.00. Zimmer Biomet Holdings, Inc. has a 12-month low of $100.39 and a 12-month high of $138.95.
Zimmer Biomet (NYSE:ZBH – Get Rating) last reported earnings on Friday, February 3rd. The medical device provider reported earnings of $1.88 per share for him in the quarter, beating analyst consensus expectations of $1.83 by $0.05. The company’s earnings for the quarter he had $1.83 billion, while analyst estimates put him at $1.76 billion. Zimmer Biomet had a return on equity of 11.97% and a net profit margin of 3.33%. Zimmer Biomet revenue increased 2.7% year-over-year. During the same quarter last year, the business earned him $1.95 per share. Analysts expect, on average, Zimmer Biomet Holdings, Inc. to post earnings per share of 7.04 for the current financial year.
Zimmer Biomet Announces Dividend
The company also recently announced a quarterly dividend payable on Friday, April 28th. Shareholders of record on Wednesday, March 29 will receive a dividend of $0.24 per share. This represents his $0.96 dividend and his 0.69% dividend yield on an annual basis. The ex-dividend date for this dividend is March 28 (Tuesday). Zimmer Biomet currently has a payout percentage of 87.27%.
Zimmer Biomet Insider Trading
In other news, Vice President Chad F. Phipps sold 23,045 shares of the company in a transaction on Friday, March 17th. The shares sold for an average of $124.50, and the total transaction value he had was $2,869,102.50. Following the transaction, Vice President now directly owns 43,671 shares of the Company stock valued at $5,437,039.50. The sale was disclosed in legal documents to the SEC that can be accessed through the SEC’s website. The insider owns his 0.95% of the company’s shares.
Zimmer Biomet company profile
Zimmer Biomet Holdings, Inc. is engaged in the design, manufacture and marketing of orthopedic reconstruction products. The company also offers sports medicine, biologics, extremity and trauma products, spine, craniomaxillofacial and thoracic products, office-based technology, dental implants, and related surgical products.
Want to know which other hedge funds hold ZBH? Visit HoldingsChannel.com to get the latest Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Rating) 13F filings and insider trading.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Listen to this before considering the Zimmer Biomet.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat has identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Zimmer Biomet is not on the list. bottom.
Zimmer Biomet currently has a ‘Hold’ rating among analysts, but the top rated analysts believe these five stocks are better buys.
See 5 stocks here